Edwards Lifesciences Co. (NYSE:EW – Get Free Report) VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total value of $347,550.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,262,521.36. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Edwards Lifesciences Price Performance
EW opened at $68.30 on Thursday. The stock has a market cap of $41.16 billion, a P/E ratio of 29.44, a P/E/G ratio of 2.83 and a beta of 1.13. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08. The company has a fifty day simple moving average of $67.59 and a 200 day simple moving average of $79.52.
Edwards Lifesciences (NYSE:EW – Get Free Report) last announced its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The company had revenue of $1.63 billion during the quarter, compared to the consensus estimate of $1.65 billion. During the same period in the prior year, the company earned $0.66 earnings per share. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. On average, research analysts expect that Edwards Lifesciences Co. will post 2.71 EPS for the current year.
Institutional Inflows and Outflows
Analysts Set New Price Targets
A number of research firms recently issued reports on EW. Jefferies Financial Group cut Edwards Lifesciences from a “buy” rating to a “hold” rating and cut their price target for the company from $85.00 to $70.00 in a report on Wednesday, September 18th. Stifel Nicolaus dropped their target price on shares of Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating for the company in a research note on Thursday, July 25th. Citigroup decreased their price target on shares of Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating on the stock in a research note on Tuesday, October 1st. Wells Fargo & Company dropped their price objective on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research report on Monday, September 9th. Finally, Deutsche Bank Aktiengesellschaft decreased their price objective on Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating on the stock in a research report on Thursday, July 25th. Fifteen equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Edwards Lifesciences has an average rating of “Hold” and a consensus target price of $75.81.
Read Our Latest Analysis on EW
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
Featured Articles
- Five stocks we like better than Edwards Lifesciences
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- How to Effectively Use the MarketBeat Ratings Screener
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- When to Sell a Stock for Profit or Loss
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.